Aura Biosciences
AURA
43 hedge funds and large institutions have $296M invested in Aura Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 9
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
32% more capital invested
Capital invested by funds: $224M → $296M (+$71.9M)
1.77% more ownership
Funds ownership: 53.98% → 55.75% (+1.8%)
2% less funds holding
Funds holding: 44 → 43 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.64M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.58M |
| 3 |
BlackRock
New York
|
+$1.92M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.18M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$873K |
| 3 |
RCM
Regency Capital Management
Honolulu,
Hawaii
|
-$455K |
| 4 |
Millennium Management
New York
|
-$325K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$61.3K |
AURA Hedge Fund Activity: Q3 2022 in Review
43 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q3 2022, worth a combined $296M — up 32% from $224M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AURA and 2 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 24 added.
The largest buyer was Adage Capital Partners, adding an estimated $2.64M. The largest seller was UBS O'Connor, cutting an estimated $1.18M.
- 43 institutional investors held Aura Biosciences (AURA) as of Q3 2022, down from 44 in Q2 2022.
- Funds reported $296M of Aura Biosciences stock for Q3 2022, up 32% quarter-over-quarter.
- 2 funds opened new Aura Biosciences positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest Aura Biosciences buyer in Q3 2022 was Adage Capital Partners, an estimated $2.64M added.
- The largest Aura Biosciences seller in Q3 2022 was UBS O'Connor, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2022.